IMPORTANT SAFETY INFORMATION

EstroGel is indicated in the treatment of moderate to severe vasomotor symptoms associated with menopause and in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using EstroGel. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find the cause.

Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots.

Do not use estrogens with or without progestins to prevent dementia. Using estrogens with or without progestins may increase your risk of dementia.

EstroGel should not be used if you have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack in the past year, currently have or have had blood clots, currently have or have had liver problems, are allergic to EstroGel or any of its ingredients, think you may be pregnant, or if you are breastfeeding.

The most commonly reported adverse events of estrogens include headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, and hair loss.

You and your healthcare provider should talk regularly about whether you still need treatment with EstroGel.

Please see full patient information (PDF).

This web site is intended for U.S. residents only.
EstroGel® is a registered trademark of LaSalle Laboratories, Inc. ©2007 ASCEND Therapeutics, Inc. All Rights Reserved.